A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2011
At a glance
- Drugs Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.